Article

Pharmaceutical Executive

Pfizer to Divest Four Injectable Products in Hospira Acquisition

August 27, 2015.

Pfizer announced on Aug. 24, 2015 that the US Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Hospira, contingent upon Pfizer’s commitment to divest four US sterile injectable assets, including acetylcysteine, clindamycin, voriconazole, and melphalan.

Pfizer also announced that Brazil’s Superintendency-General of CADE has published its unconditional clearance decision.

In a press statement, Pfizer reported an anticipated transaction close in early September.

Source: Pfizer

 

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Videos
Gen Li
Gen Li
Ted Sweetser
Ted Sweetser
Ted Sweetser